Please login to the form below

Norgine increases ProStrakan stake

Norgine has increased its stake in Scotland-based biotech ProStrakan sparking speculation that it could be to set to make a counter bid to KHK

Dutch company Norgine has raised its stake in ProStrakan to 14 per cent, which could cause Kyowa Hakko Kirin's (KHK) £292m takeover plans to falter.

At the time of writing, shares in ProStrakan stood at 132.38p, above the 130p-a-share bid agreed with the Japanese firm earlier in the week, boosted by the prospect that Norgine could be about to make a higher bid.

In mid-November, ProStrakan refused an offer from Norgine, which purchased a 13.75 per cent stake, because it was said to have undervalued the company. The Dutch company said at the time that it had "no current intention" to mount a full-scale takeover bid.

ProStrakan has a number of products in key global markets including Sancuso (granisetron transdermal), a novel skin patch for the prevention of chemotherapy-induced nausea and vomiting, and cancer pain treatment Abstral (fentanyl).

24th February 2011

PME Digital Edition

Featured jobs

Senior Developer with management potential, Healthcare Brand Com...: circa £50K

Associate Medical Director: Excellent PTO, bonus and 401k package

Medical Writer: Salary TBC

Account Manager – Creative Healthcare Advertising – Central Lond...: Salary TBC

Business Development Director – Health Education: excellent commission

SAE – Healthcare PR – Award-Winning Consultancy: Salary TBC

Account Manager- Healthcare Advertising: Negotiable

Account Manager: Negotiable

Senior Account Manager: Competitive Salary Offered

CALLING ALL SENIOR HEALTHCARE PR FREELANCERS!!!!! ACCOUNT DIRECT...: EXCELLENT DAY RATES AVAILABLE

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Systematic Reviewer - Oxford: Negotiable

Associate Director: £75, 000-90, 000

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Digital Communications Lead, Healthcare Brand and Medical Commun...: up to £50K

Account Director - Healthcare Advertising - London - HOME WORKIN...: £50000 - £68000

Healthcare Communications Account Directors x 2: Salary TBC

Editorial Manager - MedComms: DOE

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Medical Writer: Bonus Scheme, PTO &Private Healthcare

Account Manager / Senior Account Manager: 35, 000-40, 000

Healthcare Advertising Senior Account Manager / AD / Senior AD: Salary TBC

Client Services Director – Medical Education Agency – North West...: Salary TBC

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

AstraZeneca’s oncology renaissance: Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis: Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls: ‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...